Zavegepant: First Approval (vol 83, pg 825, 2023)

被引：0

作者：

Dhillon, Sohita ^{[1
]}

机构：

[1] Springer Nat, Private Bag 65901,Mairangi Bay, Auckland 0754, New Zealand

来源：

关键词：

D O I：

10.1007/s40265-023-01915-3

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页数：1

共 50 条

[41] Daridorexant: First Approval (vol 82, pg 601, 2022)
Markham, Anthony
DRUGS, 2022, 82 (07) : 841 - 841
[42] Fulzerasib: First Approval (vol 84, pg 1665, 2024)
Lamb, Yvette N.
DRUGS, 2025, 85 (02) : 281 - 281
[43] Do all roads lead to Paris? (vol 176, pg 83, 2023)
Trencher, Gregory
Blondeel, Mathieu
Asuka, Jusen
CLIMATIC CHANGE, 2023, 176 (07)
[44] The interests behind directed doxastic wrongs (vol 83, pg 235, 2023)
Dandelet, S.
ANALYSIS, 2023, 83 (04) : 751 - 753
[45] Remdesivir: A Review in COVID-19 (vol 83, pg 1215, 2023)
Blair, Hannah A.
DRUGS, 2023, 83 (14) : 1349 - 1349
[46] Japanese prime ministers and party leadership (vol 8, pg 83, 2023)
Uchiyama, Yu
ASIAN JOURNAL OF COMPARATIVE POLITICS, 2023, 8 (02) : 655 - 657
[47] Recent Work on Gender Identity and Gender (vol 83, pg 801, 2023)
Cosker-Rowland, R.
ANALYSIS, 2023, 83 (04) : 859 - 859
[48] Camrelizumab: First Global Approval (vol 79, pg 1355, 2019)
Markham, Anthony
Keam, Susan J.
DRUGS, 2019, 79 (13) : 1497 - 1497
[49] Fremanezumab: First Global Approval (vol 78, pg 1829, 2018)
Hoy, Sheridan M.
DRUGS, 2019, 79 (05) : 585 - 585
[50] Durvalumab: First Global Approval (vol 77, pg 1369, 2017)
Syed, Yahiya Y.
DRUGS, 2017, 77 (16) : 1817 - 1817